This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Program Announcement for the Defense Health Agency

Pancreatic Cancer Research Program Translational Research Partnership Award

Funding Opportunity Number: HT942526PCARPTRPA

Pre-Application Due: July 7, 2026

Application Due: October 7, 2026 https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01

FY26 Pancreatic Cancer Translational Research Partnership Award 2

Content Before You Begin 3

Basic Information Summarizes the funding opportunity, funding details, submission deadlines and review dates

Eligibility Details eligibility factors for the applicant organization and Principal Investigator

Program Description Describes the program mission and intent of the Translational Research Partnership Award; provides key award information and considerations; and outlines funding details

Application Contents Presents the two-step application process and instructions for preparing a pre-application and full application

Submission Requirements Provides locations for application packages, instructions for submitting pre-applications and full applications, and describes application verification

Application Review Information Outlines the processes for application compliance review, pre-application and full application selection/notification, and risk assessment. Also, details the review criteria for pre-application screening and both tiers of the CDMRP application review process – Peer Review and Programmatic Review

Federal Award Notices Outlines what a successful applicant can expect if recommended for funding

Post-Award Requirements References policy requirements for funded research; outlines reporting requirements and restrictions related to Principal Investigator changes and institutional award transfers

Other Information Outlines criteria for administrative actions including application rejection, modification, withdrawal and withhold

Appendix 1 Includes a checklist for all full application components to facilitate application submission

Appendix 2 Acronym List

FY26 Pancreatic Cancer Translational Research Partnership Award 3

Before You Begin

• Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission. User registration for each of these websites can take several weeks or longer.

Each applicant must ensure their registrations are active and up to date prior to application preparation.

• Read this funding opportunity announcement in the order it is written before beginning to prepare application materials. It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.

• To support application preparation, additional resources are available including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click to be taken to additional guidance and instructions within the General Application Instructions (GAI).

eBRAP Help Desk

301-682-5507 help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726 International: 1-606-545-5035 support@grants.gov

Questions regarding Grants.gov registration and Workspace.

https://sam.gov/ https://ebrap.org/eBRAP/public/index.htm https://grants.gov/register https://cdmrp.health.mil/#:%7E:text=Frequently%20Asked%20Questions%20%C2%BB https://cdmrp.health.mil/#:%7E:text=Guide%20for%20Intragovernmental%20%26%20Intramural%20Applicants https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Journey%20of%20an,Tier%20Review%20Process mailto:help@eBRAP.org mailto:support@grants.gov https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01

Section Shortcuts Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 4

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas.

• This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials.

• The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $6.60 million (M) to fund approximately six Translational Research Partnership Award applications with combined total cost caps of $1.10M. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

• Pre-Application (Preproposal) Submission Deadline: 5:00 p.m. Eastern Time (ET), July 7, 2026

• Invitation to Submit an Application: August 13, 2026

• Application Submission Deadline: 11:59 p.m. ET, October 7, 2026

• End of Application Verification Period: 5:00 p.m. ET, October 13, 2026

• Peer Review: December 2026

• Programmatic Review: January 2027 Announcement Type: Initial Funding Opportunity Number: HT942526PCARPTRPA Assistance Listing Number: 12.420

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 5

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.

2.1.2. Principal Investigator

Independent investigators at any career level affiliated with an eligible organization are eligible to be named Initiating PI or Partnering PI on the application, regardless of ethnicity, nationality or citizenship status.

At least one of the PIs (Initiating PI or Partnering PI) must have expertise in pancreatic cancer research or pancreatic cancer patient care.

An investigator may be named on only one FY26 PCARP Translational Research Partnership Award application as Initiating PI or Partnering PI.

Postdoctoral fellows, clinical fellows and equivalent are not eligible to be named Initiating PI or Partnering PI on the application.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible organizations, not to individuals. Refer to the GAI for additional recipient qualification requirements.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Content_Form_Full_App_Submission:%7E:text=pre%2Dapplication%20submission.-,Extramural%20Organization%3A,-A%20foreign%20or https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:%7E:text=Intramural%20DOW%20Organization%3A%20A%20subset%20of%20intragovernmental%20organizations%3B%20refers%20specifically%20to%20DOW%20organizations%2C%20including%20DOW%20laboratories%2C%20DOW%20military%20treatment%20facilities%2C%20and/or%20DOW%20activities%20embedded%20within%20a%20civilian%20medical%20center.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=APPENDIX%201-,RECIPIENT%20QUALIFICATION%20AND%20RESTRICTION%20INFORMATION,-A.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 6

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the PCARP. The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PCARP in 2020 to provide support for pancreatic cancer research of high potential impact and exceptional scientific merit. Appropriations for the PCARP from FY20 through FY24 totaled $66M. The FY26 appropriation is $20M.

The vision of the PCARP is to reduce the burden of pancreatic cancer among Service Members, Veterans, their Families, and the American public. The mission of the PCARP is to promote rigorous, innovative, high-impact pancreatic cancer research that leads to prevention, earlier diagnosis, new therapeutic tools, and improved outcomes.

3.1. Award History

The PCARP Translational Research Partnership Award mechanism was first offered in FY20.

Since then, 88 Translational Research Partnership Award applications were received, and 16 were recommended for funding.

3.2. Intent of the Translational Research Partnership Award

The PCARP Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award enables two independent investigators to collaborate on translational research, addressing a central problem or question in pancreatic cancer more effectively than they could through separate efforts. Both investigators must demonstrate equal intellectual input in the design of the research project. At least one partner must have expertise in pancreatic cancer research or patient care. The PCARP encourages projects that involve convergence science partnerships and inclusion of experts from outside the pancreatic cancer field. A project where one partner merely supplies tissue samples or patient access will not meet the intent of this mechanism. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials.

3.2.1. Focus Areas for Translational Research Partnership Award

• Early detection research.

• Identification and characterization of risk.

• Supportive care, quality of life and survivorship research.

• Understanding metabolic disruptions and their systemic effects, including diabetes and cachexia.

• Understanding tumor development from precursors to metastasis.

• Biomarkers to predict therapeutic response and guide management strategies.

• New therapeutic targets and approaches.

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 7

3.2.2. Key Elements for the Translational Research Partnership Award

Partnership: This mechanism requires two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. Each partner should contribute unique skills and contributions to ensure the project’s success. The proposed study must include clearly stated plans for interactions between the PIs and the institutions involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section 5.3, Submission Instructions.

Translation: The application should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan. Translational research may include correlative studies and/or development or use of annotated biorepositories. The application should demonstrate how the study will leverage clinical information to address knowledge gaps in resulting outcomes, validate key research findings, expand upon potentially transformative results and/or investigate novel findings. The ultimate goal of translational research is to move a concept or observation forward into clinical application that is relevant to active-duty Service Members, Veterans, their Families, and the American public. However, investigators should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information with an intellectual synergistic partnership.

Impact: The proposed research must have the potential to make a significant impact on pancreatic cancer research and/or patient care and accelerate the movement of promising ideas in prevention, diagnosis, detection, prognosis, treatment and/or survivorship into clinical applications.

Feasibility: The application should demonstrate that the investigators have access to the necessary specimens, data and/or intervention, as applicable.

Preliminary Data: This award mechanism requires preliminary data to support the feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Preliminary data may include published and/or unpublished results from the laboratory of the PIs or proposed collaborators that are relevant to pancreatic cancer and the proposed research project. Observations derived from a laboratory discovery, population-based studies or a clinician’s firsthand knowledge of patients and anecdotal data may drive the research idea(s).

3.2.3. Other Important Considerations for the Translational Research Partnership Award

This mechanism allows clinical research studies and small, pilot clinical trials.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:%7E:text=considered%20clinical%20trials.-,Clinical%20Research,-%3A%20For%20the https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:%7E:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 8

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families, and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 PCARP priorities.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31

USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is 3 years.

Cost Cap: The combined total costs in the applications of the Initiating PI and the Partnering PI budgeted for the entire period of performance should not exceed $1.10M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

A separate award will be made to each PI’s organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

• Support for multidisciplinary collaborations, including travel.

https://www.strobe-statement.org/ https://www.nature.com/articles/s41591-025-03635-5#:%7E:text=SPIRIT%20and%20CONSORT%20are%20evidence,relevant%20empirical%20evidence%20where%20possible https://www.nature.com/articles/s41591-025-03668-w?fromPaywallRec=false https://arriveguidelines.org/arrive-guidelines https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=Period%20of%20Performance%3A%20The%20time%20interval%20between%20the%20start%20of%20a%20federal%20award%20and%20the%20planned%20end%20date.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=in%20project%20activities.-,Cost%20Cap%3A,-The%20maximum%20cost

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 9

• Costs for up to two investigators (i.e., one for each PI’s budget) to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PCARP Translational Research Partnership Award.

• If applicable, research subject compensation and reimbursement for study-related out-of-pocket costs (e.g., travel, lodging, parking, costs associated with caregiving, and resources/equipment to enable participation).

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 10

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a pre-application submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a full application submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

The Initiating PI must submit the following pre-application components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

• Preproposal Narrative (two-page limit): The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

○ Research Idea: State the hypothesis the research will test or the objective it will reach.

State which FY26 PCARP Focus Area(s) the research will address. Detail the scientific rationale that forms the basis of the proposed project and briefly describe relevant preliminary data. Concisely state the specific aims and provide a brief overview of the study design. If the proposed research includes a clinical trial, briefly state the clinical intervention, subject population(s), and phase of the clinical trial.

o Partnership: Describe how the collaborative efforts of the PIs will result in a level of productivity greater than that achievable by each PI working independently. Describe how the combined efforts center on a unified objective and how the PIs will work together to achieve that objective from different perspectives. Briefly describe the PIs’ histories of collaborative study with each other or with other investigators, including the PIs’ abilities to function synergistically in a project among equals.

o Impact: Describe the potential impact of this study on the outcomes of individuals with pancreatic cancer, their families/caregivers and/or the understanding of pancreatic cancer.

• Pre-Application Supporting Documentation: The items to be included as supporting documentation for the pre-application must be uploaded as individual files and are limited to the following:

○ References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes https://ebrap.org/eBRAP/public/index.htm https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#Appendix2:%7E:text=APPENDIX%202.%0AFORMATTING%20GUIDELINES https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:%7E:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Full_App_Submission_Grants:%7E:text=IV.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20FULL%20APPLICATION%20SUBMISSION%20THROUGH%20GRANTS.GOV https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Full_App_Submission_eBRAP:%7E:text=V.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20FULL%20APPLICATION%20SUBMISSION%20THROUGH%20eBRAP

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 11 the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers and publisher, as appropriate).

○ List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols used in the Preproposal Narrative.

○ Key Personnel Biographical Sketches: All biographical sketches should be uploaded as a single combined file. Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

The CDMRP requires separate full application package submissions for the Initiating PI and the Partnering PI, even if the PIs are located within the same organization. The application submission process for the Partnering PI uses an abbreviated full application package.

4.3.1. Full Application Components for the Initiating PI

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only):

IMPORTANT: When completing the SF424 R&R, enter the eBRAP log number assigned during pre-application submission into Block 4a – Federal Identifier.

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

○ Attachment 1: Project Narrative (15-page limit): Upload as

“ProjectNarrative.pdf”.

Describe the proposed project in detail using the outline below.

Outline for projects without a clinical trial:

– Background: Present the ideas and scientific rationale behind the proposed research; include relevant literature citations, preliminary data and/or preclinical data that led to the development of the proposed study. Preliminary data should come from the laboratory of the PIs or member(s) of the collaborating team.

– Hypothesis(es)/Objective(s): State the hypothesis(es) the study will test and/or overall objective(s) it will reach.

– Specific Aims: Concisely explain the project’s specific aims. If this application is part of a larger study, present only tasks that this award would fund.

– Research Strategy and Feasibility:

Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for an assessment of overall project feasibility.

Provide a well-developed, well-integrated, and detailed research plan that https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=APPENDIX%202.%0AFORMATTING%20GUIDELINES https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=(a)%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20SF424%20(R%26R)%20%E2%80%93%20Application%20for%20Federal%20Assistance%20Form https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=%C2%B7-,Project%20Narrative%3A,-Attach%20as%20%E2%80%9CProjectNarrative https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Content_Form_Full_App_Submission:%7E:text=eBRAP%20User%20Name-,Biographical%20Sketch,-%3A%20This%20file

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 12 supports the translational feasibility and promise of the approach. Include specific examples of synergistic elements incorporated into the research design. Address potential problem areas and present alternative methods and approaches.

Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.

If the research includes animal studies, briefly describe the relevance of the proposed animal model and provide full details in the required Animal Research Plan (Attachment 8).

If applicable, describe and justify the appropriateness of the human subject population relative to the study objectives. If the research will involve human subjects or human biological samples, include a detailed plan for the recruitment of subjects or the acquisition of samples. Where relevant, describe the availability of and access to tissue, data, or human subjects. If applicable, provide appropriate letters of support as part of the application’s Supporting Documentation (Attachment 2).

If applicable, describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of the application’s Supporting Documentation (Attachment 2).

– Data Collection and Statistical Analysis Plan: Describe the proposed methods for data collection and analysis in a manner that is consistent with the study objectives.

Detail a statistical plan for the resulting outcomes. Include a power analysis to demonstrate the appropriateness of the sample size relative to the objectives of the study. If applicable, explain any anticipated subgroup analyses and justify the appropriateness of the sample size for the subpopulation. If applicable, describe how data will be appropriately reported and documented to support a regulatory filing with the Food and Drug Administration (FDA) or an equivalent international regulatory agency.

– Research Team: Describe how the combined backgrounds and pancreatic cancer-related experience of the research team will enable successful conduct of the project.

– Project Coordination and Communication: Describe plans for communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among both PIs and institutions participating in the project.

Outline for projects with a clinical trial:

Note: The Project Narrative is NOT the formal clinical trial protocol. Instead, the application must describe all elements of the proposed pilot clinical trial necessary for peer review as indicated below.

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 13

– Background: Present the ideas and scientific rationale behind the proposed research; include relevant literature citations, preliminary data and/or preclinical data that led to the development of the proposed study. Preliminary data should come from the laboratory of the PIs or member(s) of the collaborating team.

Clearly support the choice of study variables and explain the basis for the study question(s) and/or study hypothesis(es). Establish the relevance of the study and explain the applicability of the proposed findings.

If another funding source supported initiation of the proposed clinical trial, explain the trial’s history and background and declare the source of prior funding. Identify the portions of the study that this award would support.

– Hypothesis(es)/Objective(s): State the hypothesis(es) the study will test and/or overall objective(s) it will reach.

– Specific Aims: Concisely explain the project’s specific aims. If this application is part of a larger study, present only tasks that this award would fund.

– Research Strategy and Feasibility (include only if the application proposes laboratory research studies as a component of the project): Describe the planned laboratory research studies and how they clearly relate to the clinical trial.

Describe the experimental design, methods, analyses, potential problem areas, and alternative methods and approaches. Provide a well-developed, well-integrated, and detailed research plan that supports the translational feasibility and promise of the approach. Where relevant, describe the availability of and access to tissues, data, and/or human subjects necessary for the proposed research. If applicable, provide appropriate letters of support as part of the application’s Supporting Documentation (Attachment 2).

– Clinical Trial: Provide detailed plans for initiating, conducting, and completing the clinical trial during the period of performance. As appropriate, briefly outline a plan for obtaining regulatory approvals necessary to initiate the clinical trial (e.g., an active Investigational New Drug (IND), Investigational Device Exemption (IDE), or equivalent status). Additional details should be provided in Attachment 9: Regulatory Strategy. Describe the type of clinical trial the team will perform (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.

Identify the intervention the clinical trial will test and describe the projected outcomes.

Define the study variables and describe how the study team will measure them.

Include a description of appropriate controls and the endpoints the investigators will test.

Describe the availability of and access to critical reagents (e.g., therapeutic molecules) necessary for the clinical trial, and provide appropriate letters of support as part of the application’s Supporting Documentation (Attachment 2).

Identify the study population and specify the number of human subjects the trial will enroll. Indicate the access to the study population, recruitment plans, and inclusion/exclusion criteria. Provide appropriate letters of support demonstrating access to the study population as part of the application’s Supporting Documentation (Attachment 2). Describe the strategy for the inclusion of women

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 14 and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of subjects.

– Data Collection and Statistical Analysis Plan: Describe the proposed methods for data collection and analysis in a manner that is consistent with the study objectives.

Detail a statistical plan for the resulting outcomes. Include a power analysis to demonstrate the appropriateness of the sample size relative to the objectives of the study. If applicable, explain any anticipated subgroup analyses and justify the appropriateness of the sample size for the subpopulation. If applicable, describe how data will be appropriately reported and documented to support a regulatory filing with the FDA or an equivalent international regulatory agency.

– Clinical Team: Describe the composition of the clinical trial team. Provide details on how the team (including investigator(s), study coordinator, statistician) possesses the appropriate experience in conducting clinical trials.

– Project Coordination and Communication: Describe plans for communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among both PIs and institutions participating in the project.

○ Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support (one-page limit per letter is recommended): Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PIs have the support and resources necessary for the proposed work. Letters from the PIs’ Department Chair, or appropriate organization official, should also confirm that the PIs meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=%C2%B7-,Supporting%20Documentation%3A,-Combine%20and%20attach

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 15 populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Sex as a Biological Variable (SABV) Strategy (two-page limit is recommended):

Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

Inclusion Enrollment Report (only required if clinical research or a clinical trial is proposed): Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the “Public Health Service (PHS) Inclusion Enrollment Report”, a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.

Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

Commercialization Strategy (if applicable): Describe the commercialization plan.

The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

Research Sharing Plan: Describe the type of data or research resources to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants if applicable.

Specifically describe a plan to make animal models, tissue samples, and other resources developed as part of the proposed research project available to the scientific community, if applicable. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users.

In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

https://cdmrp.health.mil/pubs/pdf/CDMRP%20SABV%20Directive_Revised_MAR2025_signed.pdf https://cdmrp.health.mil/pubs/pdf/CDMRP%20SABV%20Directive_Revised_MAR2025_signed.pdf https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Statement%20of%20Work-,Public%20Health%20Service%20Inclusion%20Enrollment%20Report,-n/a

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 16

Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP’s expectations for making data and research resources publicly available.

○ Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: Present the scientific rationale behind the proposed research project.

State which FY26 PCARP Focus Area(s) the study will address.

Hypothesis/Objective(s): State the hypothesis the project will test and/or objective(s) it will reach. Provide evidence or rationale supporting the hypothesis(es)/objective(s).

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls.

Impact: Summarize how the proposed project is relevant to and will have an impact on the outcomes of individuals with pancreatic cancer, their families/caregivers and/or the understanding of pancreatic cancer.

Military Relevance: Describe how the proposed research is relevant to the health of Service Members, Veterans and/or their Families.

○ Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.

The lay abstract should address the points outlined below in a manner that is readily understood by readers without a background in science or medicine. Avoid overuse of scientific jargon, acronyms and abbreviations. Do not duplicate the technical abstract.

– Summarize the objectives and scientific rationale for the proposed research.

– Identify which FY26 PCARP Focus Area(s) the research will address.

– Explain the impact that the proposed research project’s results might have on the field of pancreatic cancer research and/or patient care, including the PCARP’s vision of diminishing the burden of pancreatic cancer.

– Describe the impact, in the short-term or long-term, on individuals living with pancreatic cancer, their families/caregivers and/or the understanding of pancreatic cancer.

– Explain briefly how the proposed research is relevant to the health of Service Members, Veterans, and/or their Families.

○ Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.

Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Directive%20on%20Sharing%20Data%20and%20Research%20Resources https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Suggested%20SOW%20Format https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:%7E:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=%C2%B7-,Lay%20Abstract%3A,-Attach%20as%20%E2%80%9CLayAbs https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=%C2%B7-,Technical%20Abstract%3A,-Attach%20as%20%E2%80%9CTechAbs https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:%7E:text=%C2%B7-,Statement%20of%20Work%3A,-Attach%20as%20%E2%80%9CSOW

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Pancreatic Cancer Translational Research Partnership Award 17

Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task.

○ Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”. Explain in detail the importance of the proposed project, as follows:

– Describe how the project addresses one or more of the FY26 PCARP Focus Areas as it relates to the PCARP’s goal of diminishing the burden of pancreatic cancer among Service Members, Veterans, their Families, and the American public.

– Describe the short-term impact: Detail the anticipated outcome(s)/product(s) that will directly result from the proposed research.

– Describe the long-term impact: Explain the anticipated long-term gains from the proposed research. Describe how the new understanding could ultimately lead to earlier diagnosis, new therapeutic tools and improved outcomes in patient care and the elimination of pancreatic cancer.

– If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

○ Attachment 7: Partnership Statement (one-page limit): Upload as…